Innovus Pharma announces receipt of notification to commercialize Sensum+ in the European Union.
Innovus Pharmaceuticals, Inc., an emerging over-the-counter consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today that it received the CPNP notification number required to commercialize Sensum+ in all 28 member countries of the European Union.
“We are pleased to continue to expand the commercial opportunity of our products into the European Union, the largest market after the United States,” said Innovus Pharma CEO, Dr. Bassam Damaj. “Now that we have received the CPNP notification numbers for Sensum+ and for Zestra, which we announced last week, Innovus has two products ready to be commercialized in the European Union, and therefore, expanding our ability to enter into additional commercial partnerships.”
Innovus Pharma currently partners Sensum+ internationally with Orimed in Canada, Tramorgen Limited in the United Kingdom, Elis Pharma in Turkey and certain select markets, BroadMed SAL for Lebanon, Ovation for Morocco, Khandelwal Laboratories, PVT, Inc. for India, Nepal, Bhutan, Sri Lanka and Bangladesh, Tabuk Pharma for select Middle Eastern countries, and Oz Biogenics for Myanmar and Vietnam.
Sensum+ is currently approved to be marketed and sold in 31 countries worldwide including the United States, Europe, India and Morocco. In addition to the United States, the largest market for Sensum+, Innovus Pharma currently generates Sensum+ revenues from the following markets: the United Kingdom and Morocco.
(Source: Business Wire)
